| 9.60 |  -0.40 / -4.00% |
Data as of 4:00pm ET | Day’s Change |
| 9.60 |  0.00 / 0.00% |
Volume: 23,000 |
| Previous close | 10.00 |
| Today’s open | 10.00 |
| Day’s range | 9.50 - 10.12 |
| Volume | 1,314,621 |
| Average volume (3 months) | 1,325,029 |
| Market cap | $816.2M |
| Dividend yield | -- |
| Earnings growth (last year) | +10.85% |
| Earnings growth (this year) | -20.75% |
| Earnings growth (next 5 years) | +60.00% |
| Revenue growth (last year) | +2.12% |
| P/E ratio | NM |
| Price/Sales | 24.13 |
| Price/Book | 9.96 |
| Today’s change | Today’s % change | |
|---|---|---|
| HALOHalozyme Therapeutic... | -0.42 | -5.53% |
| SZYMSolazyme Inc | -0.72 | -6.24% |
| MNTAMomenta Pharmaceutic... | +0.18 | +1.38% |
| GEVASynageva Biopharma C... | +0.77 | +1.95% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.70 |
| Annual revenue (last year) | $26.2M |
| Annual profit (last year) | -$150.1M |
| Net profit margin | -705.62% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Daniel G. Welch, MBA |
Executive VP, Chief Financial & Accounting Officer John C. Hodgman, MBA |
Corporate headquarters Brisbane, California |
.
